This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Stevanato Group (STVN) Q3 Earnings Meet Estimates
by Zacks Equity Research
Stevanato (STVN) delivered earnings and revenue surprises of 0% and 3.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Durect (DRRX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Durect (DRRX) delivered earnings and revenue surprises of -2.22% and 27.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Onconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of -3.70% and 6.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ProPhase Labs, Inc. (PRPH) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of 130% and 18.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Onconova Therapeutics, Inc. (ONTX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of -23.81% and 5%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 2.78% and 104.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Onconova Therapeutics, Inc. (ONTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of 5% and 5%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Profound Medical (PROF) delivered earnings and revenue surprises of 33.33% and 6.58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug
by Zacks Equity Research
The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022. Stock up.
Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y
by Zacks Equity Research
Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.